HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Established clinical use of octreotide and lanreotide in oncology.

Abstract
The diagnosis and treatment of neuroendocrine tumors have been significantly improved during the last decades. Localization and staging of the disease by somatostatin receptor scintigraphy (Octreoscan) are now the 'gold standard' for the management of these tumors. Treatment with somatostatin analogs has improved quality of life and possibly also survival for patients with neuroendocrine tumors. New long-acting formulations of the somatostatin analogs are as effective as the old regular formulations but will further improve quality of life for the patients. Tumor-targeted therapy with (111)In and (90)Y coupled to somatostatin analogs show promising results but await further studies.
AuthorsK Oberg
JournalChemotherapy (Chemotherapy) Vol. 47 Suppl 2 Pg. 40-53 ( 2001) ISSN: 0009-3157 [Print] Switzerland
PMID11275701 (Publication Type: Journal Article, Review)
CopyrightCopyright 2001 S. Karger AG, Basel
Chemical References
  • Antineoplastic Agents, Hormonal
  • Peptides, Cyclic
  • lanreotide
  • Somatostatin
  • Octreotide
Topics
  • Antineoplastic Agents, Hormonal (therapeutic use)
  • Humans
  • Neuroendocrine Tumors (diagnosis, drug therapy)
  • Octreotide (therapeutic use)
  • Peptides, Cyclic (therapeutic use)
  • Somatostatin (analogs & derivatives, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: